NewGenIvf Group Limited Net Income
| NIVF Stock | 0.80 0.07 9.59% |
As of the 15th of February 2026, NewGenIvf Group secures the Mean Deviation of 7.4, standard deviation of 10.5, and Risk Adjusted Performance of (0.19). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NewGenIvf Group, as well as the relationship between them. Please verify NewGenIvf Group market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if NewGenIvf Group Limited is priced some-what accurately, providing market reflects its recent price of 0.8 per share. Given that NewGenIvf Group is a hitting penny stock territory we strongly suggest to closely look at its jensen alpha.
NewGenIvf Group Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.3106 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -426.7 K | -405.4 K | |
| Net Loss | -426.7 K | -405.4 K | |
| Net Loss | (5.30) | (5.04) | |
| Net Income Per E B T | 0.49 | 0.53 |
NewGenIvf | Net Income | Build AI portfolio with NewGenIvf Stock |
The Net Income trend for NewGenIvf Group Limited offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether NewGenIvf Group is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest NewGenIvf Group's Net Income Growth Pattern
Below is the plot of the Net Income of NewGenIvf Group Limited over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in NewGenIvf Group financial statement analysis. It represents the amount of money remaining after all of NewGenIvf Group Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is NewGenIvf Group's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewGenIvf Group's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (474.1 K) | 10 Years Trend |
|
Net Income |
| Timeline |
NewGenIvf Net Income Regression Statistics
| Arithmetic Mean | (99,115) | |
| Geometric Mean | 4,018 | |
| Coefficient Of Variation | (278.72) | |
| Mean Deviation | 204,796 | |
| Median | (533.00) | |
| Standard Deviation | 276,249 | |
| Sample Variance | 76.3B | |
| Range | 1.1M | |
| R-Value | (0.52) | |
| Mean Square Error | 59.2B | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | (28,559) | |
| Total Sum of Squares | 1.2T |
NewGenIvf Net Income History
Other Fundumenentals of NewGenIvf Group
NewGenIvf Group Net Income component correlations
NewGenIvf Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for NewGenIvf Group is extremely important. It helps to project a fair market value of NewGenIvf Stock properly, considering its historical fundamentals such as Net Income. Since NewGenIvf Group's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewGenIvf Group's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewGenIvf Group's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Health Care Providers & Services industry sustain growth momentum? Does NewGenIvf have expansion opportunities? Factors like these will boost the valuation of NewGenIvf Group. Anticipated expansion of NewGenIvf directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating NewGenIvf Group demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share 4.2 K | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Understanding NewGenIvf Group requires distinguishing between market price and book value, where the latter reflects NewGenIvf's accounting equity. The concept of intrinsic value - what NewGenIvf Group's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push NewGenIvf Group's price substantially above or below its fundamental value.
It's important to distinguish between NewGenIvf Group's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewGenIvf Group should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NewGenIvf Group's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
NewGenIvf Group 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NewGenIvf Group's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NewGenIvf Group.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in NewGenIvf Group on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding NewGenIvf Group Limited or generate 0.0% return on investment in NewGenIvf Group over 90 days. NewGenIvf Group is related to or competes with Scworx Corp, ZyVersa Therapeutics, Conduit Pharmaceuticals, INVO Fertility, Envoy Medical, PetVivo Holdings, and Concord Medical. NewGenIvf Group is entity of United States More
NewGenIvf Group Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NewGenIvf Group's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NewGenIvf Group Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.25) | |||
| Maximum Drawdown | 53.65 | |||
| Value At Risk | (21.23) | |||
| Potential Upside | 15.95 |
NewGenIvf Group Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewGenIvf Group's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NewGenIvf Group's standard deviation. In reality, there are many statistical measures that can use NewGenIvf Group historical prices to predict the future NewGenIvf Group's volatility.| Risk Adjusted Performance | (0.19) | |||
| Jensen Alpha | (2.68) | |||
| Total Risk Alpha | (3.36) | |||
| Treynor Ratio | (1.71) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NewGenIvf Group's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NewGenIvf Group February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.19) | |||
| Market Risk Adjusted Performance | (1.70) | |||
| Mean Deviation | 7.4 | |||
| Coefficient Of Variation | (407.83) | |||
| Standard Deviation | 10.5 | |||
| Variance | 110.24 | |||
| Information Ratio | (0.25) | |||
| Jensen Alpha | (2.68) | |||
| Total Risk Alpha | (3.36) | |||
| Treynor Ratio | (1.71) | |||
| Maximum Drawdown | 53.65 | |||
| Value At Risk | (21.23) | |||
| Potential Upside | 15.95 | |||
| Skewness | (0.05) | |||
| Kurtosis | 0.9593 |
NewGenIvf Group Backtested Returns
NewGenIvf Group has Sharpe Ratio of -0.22, which conveys that the firm had a -0.22 % return per unit of risk over the last 3 months. NewGenIvf Group exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify NewGenIvf Group's Risk Adjusted Performance of (0.19), mean deviation of 7.4, and Standard Deviation of 10.5 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.51, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NewGenIvf Group will likely underperform. At this point, NewGenIvf Group has a negative expected return of -2.4%. Please make sure to verify NewGenIvf Group's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if NewGenIvf Group performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.87 |
Very good predictability
NewGenIvf Group Limited has very good predictability. Overlapping area represents the amount of predictability between NewGenIvf Group time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NewGenIvf Group price movement. The serial correlation of 0.87 indicates that approximately 87.0% of current NewGenIvf Group price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.87 | |
| Spearman Rank Test | 0.8 | |
| Residual Average | 0.0 | |
| Price Variance | 0.16 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
NewGenIvf Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, NewGenIvf Group Limited reported net income of (474,101). This is 100.14% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.08% higher than that of the company.
NewGenIvf Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewGenIvf Group's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewGenIvf Group could also be used in its relative valuation, which is a method of valuing NewGenIvf Group by comparing valuation metrics of similar companies.NewGenIvf Group is currently under evaluation in net income category among its peers.
NewGenIvf Fundamentals
| Return On Equity | 1.61 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | 3.81 % | ||||
| Operating Margin | (1.96) % | ||||
| Current Valuation | 6 M | ||||
| Shares Outstanding | 982.69 K | ||||
| Shares Owned By Insiders | 0.13 % | ||||
| Shares Owned By Institutions | 1.08 % | ||||
| Number Of Shares Shorted | 64.2 K | ||||
| Price To Book | 0.03 X | ||||
| Price To Sales | 0.17 X | ||||
| Revenue | 5.43 M | ||||
| Gross Profit | 970.96 K | ||||
| EBITDA | 24.26 K | ||||
| Net Income | (474.1 K) | ||||
| Total Debt | 3.03 M | ||||
| Book Value Per Share | 204.69 X | ||||
| Cash Flow From Operations | (8.26 M) | ||||
| Short Ratio | 0.07 X | ||||
| Earnings Per Share | 4,195 X | ||||
| Target Price | 225.0 | ||||
| Number Of Employees | 76 | ||||
| Beta | -0.045 | ||||
| Market Capitalization | 788.24 K | ||||
| Total Asset | 3.58 M | ||||
| Retained Earnings | (985.99 K) | ||||
| Working Capital | 452.39 K | ||||
| Net Asset | 3.58 M |
About NewGenIvf Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewGenIvf Group Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewGenIvf Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewGenIvf Group Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Can Health Care Providers & Services industry sustain growth momentum? Does NewGenIvf have expansion opportunities? Factors like these will boost the valuation of NewGenIvf Group. Anticipated expansion of NewGenIvf directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating NewGenIvf Group demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share 4.2 K | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Understanding NewGenIvf Group requires distinguishing between market price and book value, where the latter reflects NewGenIvf's accounting equity. The concept of intrinsic value - what NewGenIvf Group's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push NewGenIvf Group's price substantially above or below its fundamental value.
It's important to distinguish between NewGenIvf Group's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewGenIvf Group should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NewGenIvf Group's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.